A topline review of 3 more of the top 6 studies of 2017 in afib includes the death of digoxin, go and no-go foods, and afib and ESRD.
Atrial Fibrillation May be More Common in Younger Adults than Previously Thought: Daily Dose
Your daily dose of the clinical news you may have missed.
Women and Heart Disease: Incidence, Prevalence, Progress, and the Future
Female CV mortality lags behind male mortality; lifetime risk assessment, not 10-year risk, is a better estimation tool for women
Concomitant SSRI and DOAC Use Increases Risk of Major Bleeding, Including ICH: New Findings
Overall, a 33% increased risk of major bleeding was seen, with risk highest during the first 30 days of concomitant use and persistent, but lower, after 6 months.
The Great Beta-Blocker Debate: The Pros and Cons
Newly diagnosed hypertension in a patient whose blood pressure is 152/94 mm Hg. What agents will you consider for this patient? Beta-blockers? Think again.
Apixaban and Aspirin Appear Equal Against Recurrent Stroke in Individuals with Cardiopathy
Anticoagulation and antiplatelet therapy appeared equally effective in reducing risk of recurrent stroke following cryptogenic stroke in persons with evidence of atrial cardiopathy.
Apixaban Reduced Risk of Stroke in Subclinical Afib Relative to Aspirin but with Greater Risk of Bleeding: ARTRESIA Trial
In apixaban-treated participants, risk of stroke or systemic embolism was reduced by 37%; the risk of disability or fatal stroke declined by 49%, but with noted bleeding risk.